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976Objective: Video-assisted thoracoscopic lobectomy remains controversial. We compared outcomes from partic-
ipants in a randomized study comparing lymph node sampling versus dissection for early-stage lung cancer who
underwent either video-assisted thoracoscopic or open lobectomy.
Methods: Data from 964 participants in the American College of Surgeons Oncology Group Z0030 trial were
used to construct propensity scores for video-assisted thoracoscopic versus open lobectomy (based on age, gen-
der, histology, performance status, tumor location, and T1 vs T2). Propensity scores were used to estimate the
adjusted risks of short-term outcomes of surgery. Patients were classified into 5 equal-sized groups and compared
using conditional logistic regression or repeated measures analysis of variance.
Results: A total of 752 patients (66 video-assisted and 686 open procedures) were analyzed on the basis of
propensity score stratification. Median operative time was shorter for video-assisted thoracoscopic lobectomy
(video-assisted thoracoscopy 117.5 minutes vs open 171.5 minutes; P< .001). Median total number of lymph
nodes retrieved (dissection group only) was similar (video-assisted thoracoscopy 15 nodes vs open 19 nodes;
P ¼ .147), as were instances of R1/R2 resection (video-assisted thoracoscopy 0% vs open 2.3%; P ¼ .368).
Patients undergoing video-assisted thoracoscopic lobectomy had less atelectasis requiring bronchoscopy (0%
vs 6.3%, P ¼ .035), fewer chest tubes draining greater than 7 days (1.5% vs 10.8%; P ¼ .029), and shorter me-
dian length of stay (5 days vs 7 days; P<.001). Operative mortality was similar (video-assisted thoracoscopy 0%
vs open 1.6%, P ¼ 1.0).
Conclusion: Patients undergoing video-assisted lobectomy had fewer respiratory complications and shorter
length of stay. These data suggest video-assisted thoracoscopic lobectomy is safe in patients with resectable
lung cancer. Longer follow-up is needed to determine the oncologic equivalency of video-assisted versus open
lobectomy. (J Thorac Cardiovasc Surg 2010;139:976-83)The potential benefits of video-assisted thoracoscopic
(VATS) lobectomy include faster patient recovery, fewer
complications, and shorter hospital stay without compromis-
ing the oncologic aspects of the operation. However, the rou-
tine use of VATS lobectomy for the treatment of resectable
non–small cell lung cancer (NSCLC) remains controversial.
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The Journal of Thoracic and Cardiovascular Surgrandomized trials,1-4 a multicenter phase II study,5 case-con-
trol series,6-9 and a large retrospective series.10 Two recent
meta-analyses have been published.6,7 The randomized trials
enrolled relatively small numbers of patients, and retrospec-
tive case series are subject to selection biases. Recent publi-
cations have been case-control series.8,9
The American College of Surgeons Oncology Group
(ACOSOG) Z0030 clinical trial provided an opportunity to
retrospectively compare VATS lobectomy with open lobec-
tomy.11 Z0030 is a randomized, prospective, multi-institu-
tional clinical trial that was designed to determine the
effect on survival of lymph node sampling versusmediastinal
lymph node dissection in patients undergoing complete
resection of early-stage NSCLC. A secondary objective
was to determine the relative morbidity of the 2 techniques.
Although the final study end points of survival have not
been reported, data on short-term outcomes after lung resec-
tion are available.11 We used propensity score-based match-
ing12 to compare the short-term clinical outcomes of 2 groups
of patients who enrolled in the trial: those who underwent
VATS lobectomy and thosewho underwent open lobectomy.ery c April 2010
Abbreviations and Acronyms
ACOSOG ¼ American College of Surgeons
Oncology Group
CI ¼ confidence interval
NSCLC ¼ non–small cell lung cancer
RR ¼ relative risk
VATS ¼ video-assisted thoracoscopic
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The details of the study design, eligibility requirements, and morbidity
and mortality for patients enrolled in the ACOSOG Z0030 trial have been
reported. In summary,11 eligible patients were required to be 18 years of
age or older, to have an Eastern Cooperative Oncology Group performance
score less than 3, and to have a tissue diagnosis of a clinically resectable T1
or T2, N0 or non-hilar N1, M0NSCLC (squamous cell carcinoma, large cell
carcinoma, or adenocarcinoma, including bronchoalveolar carcinoma) es-
tablished before randomization. Patients underwent computed tomography
of the chest and upper abdomen, including the liver and adrenal glands
within 60 days of the pulmonary resection. Patients who had a pre-thoracot-
omy mediastinoscopy were eligible if no mediastinal lymph node metasta-
ses were identified. Patients who did not undergo mediastinoscopy were
eligible if they had no evidence of mediastinal lymphadenopathy by com-
puted tomography criteria (>1.0 cm in the shortest axis). Eligible patients
had to be candidates for a complete resection of the carcinoma by means
of pneumonectomy, lobectomy, bilobectomy, or anatomic segmentectomy,
with or without sleeve resection. The type of resection (VATS or open) was
not specified in the protocol. Exclusion criteria included patients with T3 or
T4 tumors, patients who were treated with pulmonary wedge excision, and
patients who received prior chemotherapy or radiation therapy for their can-
cer. Additional intraoperative eligibility criteria included pre-randomization
sampling of designated lymph node stations. Patients with N2 metastases on
frozen section were excluded from randomization. Therefore, all patients in
ACOSOG Z0030 had as a minimum either mediastinoscopy and/or intrao-
perative lymph node sampling for nodal staging.
All surgeons who participated in the trial were general thoracic surgeons.
The enrolling surgeons were required to read a description of the procedure
and watch a video of the mediastinal lymph node dissection technique be-
fore enrolling their first patient into the trial. Each operative note was re-
viewed by the principle investigators for completeness of the dissection
and adherence to the protocol. All patients provided written informed con-
sent before trial enrollment in accordance with applicable guidelines. The
ACOSOG Z0030 trial was approved by a local Human Investigations Com-
mittee and in accord with an assurance filed with and approved by the De-
partment of Health and Human Services.
We reviewed the ACOSOG Z0030 data set and identified 964 patients
(66 with VATS and 898 with open lobectomy) who underwent lobectomy,
bilobectomy, or anatomic segmentectomy. Those who underwent pneumo-
nectomy or wedge resection alone were excluded from this analysis. Pa-
tients who underwent VATS wedge resection for diagnosis and then open
thoracotomy and resection as described above were included in the ‘‘open
lobectomy’’ group.
Differences between groups in clinical and tumor characteristics were
compared using the 2-sample rank test or chi-square test as appropriate.
Clinical and tumor characteristics were used to build a propensity score
for choice of treatments.12-14 These variables included age, gender, histol-
ogy, performance status, tumor location, and clinical stage (T1 vs T2). Pro-
pensity scores were developed to estimate the adjusted risks of perioperative
outcomes associated with the choice of treatment (VATS vs open). Logistic
regression was used to estimate the probability of VATS versus open givenThe Journal of Thoracic and Cathe previously listed risk factors. Patients were classified into 7 groups on
the basis of their propensity scores. A total of 208 patients undergoing tho-
racotomy had lower scores than the lowest score of any patient treated with
VATS (group 0); 4 patients undergoing open lobectomy had higher scores
than the highest score of any patient treated with VATS (group 6). Patients
from these 2 groups were omitted from further analysis. The remaining 752
patients (66 in the VATS group and 686 in the open lobectomy group) were
classified into 5 equal-sized propensity score groups (groups 1–5). Condi-
tional logistic regression with 5 strata (propensity score groups 1–5) for di-
chotomous outcomes and repeated-measures analysis of variance with strata
as a repeated factor for continuous outcomes were used to compare out-
comes between VATS and open cases.
The 66 patients in the VATS groupwere older than the 686 patients in the
open group, with a median age of 72.9 years (mean  standard deviation,
70.9  9.7) compared with 68.6 years (mean  standard deviation, 68.1
 8.8; P ¼ .011) (Table 1). Despite the age difference, there was a higher
percentage of patients with performance status 0 in the VATS group com-
pared with the open group (90.9% vs 71.1%; P ¼ .002). There was also
a difference in histology with a higher percentage of adenocarcinoma in
the VATS group compared with the open group. In the VATS cohort, 44
patients (66.7%) presented with T1 tumors and 22 patients (33.3%) pre-
sented with T2 tumors. In the open cohort, 408 patients (59.5%) presented
with T1 tumors and 278 patients (40.5%) presented with T2 tumors (P ¼
.255). The distribution of tumor location was similar for each group with
most tumors in the upper lobes of the lung (Table 1). Because the variables
of age, gender, histology, performance status, tumor location, and clinical
stage (T1 vs T2) were included in the propensity score model, the differ-
ences between the groups demonstrated in Table 1 were adjusted for in
the statistical analysis.
The VATS group consisted of 66 patients from 8 institutions, and the
open lobectomy group consisted of 686 patients from 71 institutions. The
highest accruing surgeon to the VATS lobectomy group contributed 54 of
66 patients (82%).RESULTS
Perioperative outcomes are reported in Table 2. Operative
mortality was similar for the 2 cohorts. Median operative
time was shorter for the VATS cohort compared with the
open group. The occurrence of bleeding requiring transfu-
sion and the number of instances of bleeding requiring reop-
eration were each similar for the 2 cohorts. The median
amount of chest tube drainage was less for the VATS group,
as was the duration of chest tube drainage. Median hospital
length of stay was also less for the VATS group compared
with the open group (5 vs 7 days; P< .001). The incidence
of microscopic (R1) or grossly positive (R2) resection mar-
gins was similar for each group. Because this is a post hoc
analysis of data from a trial that randomized patients be-
tween lymph node sampling and dissection, we specifically
analyzed those patients who were randomized to receive
lymph node dissection. The median number of lymph
node stations sampled was similar for the 2 cohorts, as
was the median number of lymph nodes that were removed
from each group.
A list of complications for both groups is provided inTable
3. Instances of chest tube drainage lasting more than 7 days
were noted less often in the VATS group compared with
the open group, whereas the occurrence of air leak lastingrdiovascular Surgery c Volume 139, Number 4 977
TABLE 1. Characteristics of subjects in each group
Variable VATS (n ¼ 66) Open (n ¼ 686) P*
Age, y 72.9; 70.9  9.7 68.6; 68.1  8.8 .011
Gender .148
Female 38 (57.6) 331 (48.3)
Male 28 (42.4) 355 (51.8)
Histology .029
Squamous 10 (15.2) 206 (30.0)
Adenocarcinoma 45 (68.2) 354 (51.6)
Large cell 2 (3.0) 36 (5.3)
Bronchoalveolar 8 (12.1) 57 (8.3)
Other non–small cell 1 (1.5) 33 (4.8)
ECOG performance status .002
0 60 (90.9) 488 (71.1)
1 5 (7.6) 192 (28.0)
2 1 (1.5) 6 (0.9)
Tumor locationy
RUL 32 (48.5) 284 (41.4) .265
RML 2 (3.0) 44 (6.4) .273
RLL 8 (12.1) 112 (16.3) .373
LUL 18 (27.3) 173 (25.2) .714
LLL 7 (10.6) 85 (12.4) .673
Clinical stage .255
T1 44 (66.7) 408 (59.5)
T2 22 (33.3) 278 (40.5)
Procedure performed
Lobectomy 63 (95.5) 606 (88.3) .078
Bilobectomy 1 (1.5) 27 (3.9) .502
Segmentectomy 3 (4.6) 54 (7.9) .330
ECOG, Eastern Cooperative Oncology Group; RUL, right upper lobe; RML, right mid-
dle lobe; RLL, right left lobe; LUL, left upper lobe; LLL, left lower lobe. Values are n
(%) or median; mean  standard deviation. *Chi-square test for categoric variables
and 2-sample rank sum test for continuous variables. yMultiple tumor locations.
TABLE 2. Perioperative outcomes
VATS (n ¼ 66) Open (n ¼ 686) P*
Operative time, min 117.5; 61–450 171.5; 40–425 <.001
Lymph node stations
sampledy
7 (5–11) 7 (3–13) .418
Lymph nodes retrievedy 15; 5–48 19; 2–83 .147
R1/R2 resection, n (%) 0 (0) 16 (2.3) .368
Chest tube drainage, mLz 987; 140–3382 1504.5; 8–25,139 .001
Hospital length of stay, n (%)x 4.5; 1–19 7; 0–99 <.001
Operative mortality, n (%) 0 (0) 11 (1.6) 1.0
VATS, Video-assisted thoracoscopy. Values are median; range unless specified by n
(%). *Conditional logistic regression for categoric variables (exact tests when appro-
priate) and repeated-measure analysis of variance for continuous variables accounting
for the propensity score stratification. yLymph node dissection cases only (29 in the
VATS group and 353 in the OPEN group); data were missing for 1 subject in the tho-
racotomy group for lymph nodes retrieved. zData were missing for 12 subjects in the
thoracotomy group. xData were missing for 2 subjects in the thoracotomy group.
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ratory distress syndrome, chylothorax, and respiratory failure
requiring ventilation occurred infrequently in both cohorts;
however, atelectasis or secretion retention requiring bron-
choscopy occurred less often in the VATS group. The prev-
alence of all other complications was similar for the 2
cohorts. Significantly fewer patients in the VATS group
(18/66, 27.3%) experienced at least 1 complication com-
pared with the open group (327/686, 47.8%; P ¼ .005).DISCUSSION
VATS is widely accepted for certain indications, but the
use of this technique to perform anatomic lung resection
for lung cancer remains controversial. The potential advan-
tages of VATS lobectomy include a smaller incision with
better postoperative mechanics and less postoperative pain,
a lower incidence of postoperative atrial arrhythmias, fewer
respiratory complications, earlier chest tube removal, and
a shorter length of hospital stay, among others. Supporters
believe that VATS lobectomy can be performed while pre-
serving the oncologic principles of open lobectomy in terms
of the ability to achieve a complete (R0) resection and per-978 The Journal of Thoracic and Cardiovascular Surgform an adequate lymph node dissection. Similar overall
5-year survival was noted in a randomized trial comparing
VATS with open lobectomy.2 Critics would point out that
another randomized trial demonstrated no clear advantages
to the use of VATS lobectomy because patients experienced
a similar length of stay and perioperative morbidity1 and that
the majority of data supporting VATS lobectomy have been
in the form of retrospective case series, with only a few large
case-control series reported.7
We examined the database of the ACOSOG Z0030 clini-
cal trial to identify patients who underwent anatomic lung
resection (lobectomy, bilobectomy, or segmentectomy)
through a VATS or open approach with the goal of perform-
ing a case-control study that would compare VATS lobec-
tomy with open lobectomy. There are several advantages
to using the ACOSOG Z0030 data set, including the fact
that this was a large (1023 patients) prospective, multicenter,
phase III clinical trial.11 Strict eligibility criteria for enroll-
ment were used, and patients underwent a standardized pre-
operative clinical and imaging evaluation with computed
tomography scans performed within 60 days of surgery.
Operative reports were reviewed by 1 of 2 main investiga-
tors. Data collection was prospective, uniform, and of high
quality. Collection of data regarding outcomes and compli-
cations was standardized as to the definitions and types of
variables collected. However, this was a secondary analysis
of data from a randomized trial originally designed to com-
pare the results of lymph node sampling with those of lymph
node dissection in patients with resectable lung cancer. Not
unexpectedly, we observed important baseline differences in
the VATS lobectomy group compared with the open lobec-
tomy group (Table 1). The patients in the VATS group were
older, were more likely to have non-squamous histology,
and had a better Eastern Cooperative Oncology Group
performance status; in addition, most were operated on by
1 surgeon.ery c April 2010
TABLE 3. List of complications
Variable VATS (n ¼ 66) Open* (n ¼ 686) Py OR 95% CI
Air leak>7 d 1 (1.5) 50 (7.3) 0.23 0.01–1.46 .155
Chest tube drainage>7 d 1 (1.5) 74 (10.8) 0.15 0.004–0.9 .029
Chylothorax, stopped spontaneously 0 (0) 1 (0.2) 1.0
Chylothorax, required reoperation 0 (0) 6 (0.9) 1.0
Hemorrhage, required transfusion 2 (3.0) 13 (1.9) 1.17 0.12–6.03 .69
Hemorrhage, required reoperation 1 (1.5) 9 (1.3) 1.02 0.02–8.32 1.0
Atelectasis or secretional retention, requiring bronchoscopy 0 (0) 43 (6.3) .035
Recurrent nerve palsy 0 (0) 3 (0.4)
Phrenic nerve palsy 0 (0) 3 (0.4) 1.0
Atrial arrhythmia 6 (9.1) 88 (12.9) 0.53 0.18–1.31 .185
Ventricular arrhythmia 0 (0) 8 (1.2) .587
Respiratory failure, requiring ventilation 0 (0) 5 (3.7) .381
MI 1 (1.5) 6 (0.9) 1.56 0.03–16.0 .538
CVA 0 (0) 3 (0.4) 1.0
DVT 0 (0) 5 (0.7) 1.0
BP fistula 0 (0) 1 (0.2) 1.0
Empyema 1 (1.5) 3 (0.4) .473
Wound infection 0 (0) 3 (0.4) 1.0
Sepsis 0 (0) 3 (0.4) 1.0
ARDS 0 (0) 2 (0.3) 1.0
Pulmonary embolus 0 (0) 4 (0.6) 1.0
Other postoperative outcome 12 (18.2) 195 (28.5) 0.63 0.30–1.26 .218
At least 1 complication 18 (27.3) 327 (47.8) 0.44 0.23–0.81 .005
ARDS, Adult respiratory disease syndrome; BP, bronchopleural; CI, confidence interval; CVA, cerebrovascular accident; DVT, deep vein thrombosis; MI, myocardial infarction;
OR, odds ratio; VATS, video-assisted thoracoscopy. OR and CI are presented for outcomes with  1% in each group. *Data were unavailable for 2 subjects in the open lobectomy
group. yConditional logistic regression accounting for the propensity score stratification. Exact tests were appropriate.
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comparison, we analyzed the data using the technique of
propensity scores, a method of case-matching. Propensity
scores are a class of multivariate statistical methods that
identify groups of patients who have similar chances of re-
ceiving one treatment or another from within a given study
population. Using propensity scores avoids some of the
problems associated with case matching by creating a model
where the differences between the groups are ‘‘compressed’’
into a single score.12 In this analysis, age, gender, histology,
performance status, tumor location, and clinical T stage (T1
vs T2) were used to build a propensity score for choice of
treatment. Significant differences in outcomes between treat-
ment groups can then be attributed to the difference in treat-
ments as long as the patients in the different treatment groups
have similar propensity scores. However, we were not able
to include the variable of operating surgeon in our propen-
sity score model, and therefore this remains an unresolved
potential source of confounding in this analysis. A total of
9 surgeons performed VATS lung resections in the ACO-
SOG Z0030 trial. However, a single surgeon performed
most of the VATS procedures. This means that one cannot
exclude the possibility that the results achieved in the
VATS group were due to the surgeon and hospital perform-The Journal of Thoracic and Caing the VATS procedures and not just to the fact that the pa-
tient underwent a VATS procedure.
The main finding of this secondary analysis of data from
the ACOSOG Z0030 trial is that, after matching for preop-
erative variables such as age, gender, performance status,
histology and T stage, patients who underwent VATS lobec-
tomy had a statistically significant shorter median length of
stay compared with the open group. A decrease in postoper-
ative length of stay after VATS lobectomy has been reported
by many but not all studies comparing clinical outcomes of
VATS lobectomy and open thoracotomy and lobectomy.6,7
This has been variously attributed to decreased postopera-
tive pain or earlier removal of chest tubes in patients under-
going VATS lobectomy. In the current study, we observed
fewer instances of chest tube drainage lasting greater than
7 days in the VATS group compared with the open group de-
spite similar occurrences of air leak lasting greater than 7
days. Median total chest tube drainage was also significantly
less for the VATS group compared with the open group.
Data regarding postoperative pain were not collected in pa-
tients enrolled in the Z0030 trial; therefore, we cannot com-
ment on the likelihood that decreased pain contributed to the
shorter postoperative length of stay observed in the VATS
group. In addition, as others have pointed out, chest tuberdiovascular Surgery c Volume 139, Number 4 979
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performing and not performing VATS lobectomy.6 Parame-
ters for chest tube management were not defined in the
ACOSOG Z0030 trial; therefore, the effect of institutional
and surgeon differences in chest tube management cannot
be excluded as an explanation for the observations that
were identified in this analysis.
Another proposed benefit of VATS lobectomy has been
a decrease in postoperative complications. In the current
analysis, we observed that the median number of patients ex-
periencing at least 1 complication was lower in the VATS
group. This is similar to the report of Park and colleagues,8
who matched 122 patients undergoing VATS lobectomy
with 122 patients undergoing open lobectomy and observed
fewer overall complications in the VATS group. In addition
to the decreased likelihood of chest tube drainage lasting
more than 7 days for the VATS group that was mentioned
above, we observed that patients in the VATS cohort under-
went fewer postoperative bronchoscopies for atelectasis or
secretion retention. This finding may be related to the com-
bination of decreased pain, inflammation, and better mobili-
zation of secretions because of improved postoperative chest
wall function in the VATS lobectomy group. A decrease in
postoperative respiratory complications after VATS lobec-
tomy compared with open lobectomy has been shown in
some studies, especially in the elderly,9 but not in other
analyses.6,7
We noted a similar prevalence of atrial fibrillation in both
the VATS and open lobectomy groups, a finding that others
have also reported.8 This would suggest that the mechanical
effects of dividing pulmonary vessels, denervation, or other
neurohumoral factors related to lung resection per se rather
than effects related to the size of the incision were responsi-
ble for postoperative arrhythmias. The recent meta-analysis
by Yan and colleagues7 found that the occurrence of postop-
erative arrhythmias (based on an analysis of 5 studies) in
VATS lobectomy cases compared with open lobectomy
cases was similar (relative risk [RR], 0.99; 95% confidence
interval [CI], 0.52–1.91; P ¼ .98). The current analysis
found that the occurrence of other cardiovascular complica-
tions (myocardial infarction, stroke, pulmonary embolus, or
ventricular arrhythmias) was similar for the 2 groups. Fi-
nally, the number of instances of bleeding requiring transfu-
sion or reoperation was also similar for the 2 cohorts.
Survival data are pending for the ACOSOG Z0030 study
participants, so the oncologic efficacy of VATS and open lo-
bectomy cannot be determined from the current analysis.
However, the median number of R1 or R2 resections was
similar for the 2 groups, supporting the concept that
VATS lobectomy is an oncologically sound operation.
Critics of the VATS approach have raised concerns about
the adequacy of lymph node dissection compared with
open lobectomy.We found that in those patients randomized
to lymph node dissection, the number of lymph node stations980 The Journal of Thoracic and Cardiovascular Surgsampled and the total number of lymph nodes removed were
similar for both VATS lobectomy and open lobectomy.
Kirby and colleagues,1 in a randomized trial, noted no differ-
ence in the total number of lymph nodes sampled in VATS
lobectomy compared with muscle-sparing thoracotomy and
lobectomy (total number of lymph nodes: VATS 9.5  3.6
vs muscle-sparing thoracotomy 9.3 4.3). In 2002, Sagawa
and colleagues15 performed VATS lobectomy and lymph
node dissection followed by immediate thoracotomy to
look for ‘‘remnant’’ lymph nodes in 29 patients. They found
an average of 1.2 remnant nodes of an average total of 40.3
lymph nodes for right-sided cases and 1.2 remnant nodes of
an average total of 37.1 nodes for left-sided cases. Watanabe
and colleagues16 examined lymph nodes from 350 patients
undergoing lobectomy with systematic lymph node dissec-
tion (191 VATS cases and 159 open lobectomy cases) and
found that the total number of mediastinal lymph nodes dis-
sected was similar for each group. A recent meta-analysis of
21 studies (2 randomized and 19 nonrandomized) performed
by Yan and colleagues7 found similar local recurrence rates
for VATS lobectomy compared with open lobectomy
(RR, 0.64; 95% CI, 0.35–1.35; P ¼ .24). Their analysis
suggested that VATS lobectomy for lung cancer was associ-
ated with a reduced systemic recurrence rate (RR, 0.57; 95%
CI, 0.3–0.95; P ¼ .03) and improved 5-year all-cause
mortality rate for VATS (RR, 0.66; 95% CI, 0.45–0.97;
P ¼ .04).
CONCLUSIONS
This secondary analysis of data from ACOSOG Z0030
suggests that VATS lobectomy is an appropriate procedure
for the treatment of early-stage lung cancer in terms of mor-
tality and complications when compared with open lobec-
tomy. VATS lobectomy may offer advantages in terms of
decreased length of stay and overall fewer complications.
However, the results of this analysis should be interpreted
carefully. Although we used propensity scores to adjust
for important baseline differences, such as age, gender, per-
formance status, histology, and T1 or T2 stage between the
VATS lobectomy and open lobectomy groups, we were not
able to include the variable of operating surgeon in our pro-
pensity score model. This remains an unresolved potential
source of confounding in this analysis. The outcomes ob-
served for VATS lobectomy are inextricably linked with
the surgeon and hospital center that enrolled most of those
patients into the ACOSOG Z0030 trial. However, the cur-
rent authors believe that we have done all that we can to
make the comparisons between the VATS and open lobec-
tomy cohorts as fair as possible. Long-term follow-up data
are needed to judge the oncologic equivalence of the 2 ap-
proaches. The mature results of ACOSOG Z0030 should
provide more information regarding local recurrence and
overall survival of those patients undergoing VATS lobec-
tomy versus open lobectomy.ery c April 2010
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Dr John D. Mitchell, MD (Denver, Colo). The ACOSOG Z30
studywas a randomizedmulti-institutional prospective trial designed
to assess the relative merits of mediastinal lymph node dissection
versus sampling in patients with early-stage lung cancer, both in
terms of the perioperative morbidity of the 2 procedures and the
long-term oncologic outcomes. Thefirst has been reported, asWalter
said, and we await the data regarding recurrence and survival.
This current study examines a subset of the Z30 patients who un-
derwent a lobectomy, bilobectomy, or segmentectomy. Through
the magic of propensity scoring, these patients have been distilled
down into 2 matched groups: 66 patients who underwent anatomicThe Journal of Thoracic and Calung resection via a thoracoscopic approach and 686 patients who
had an open procedure. The VATS group had shorter operative
times, less chest tube drainage, shorter chest tube duration, shorter
hospitals stays, less respiratory problems requiring intervention,
and less complications overall. I was gratified to see that your find-
ings matched my own personal observations about VATS proce-
dures, but I have a couple questions for you.
First, the majority of the VATS procedures, 82%, were done by
1 surgeon. How do we really know that the differences that you are
reporting today are related to the 2 different surgical approaches?
An alternative possibility is that these results just reflect practice
differences between the surgeon and the rest of the ACOSOG par-
ticipants. For example, if the VATS surgeon in question is more lib-
eral with chest tube removal, with less regard for the output, the
chest tube duration is going to be shorter, and the hospital stay
will probably be shorter.
Dr Scott. That is the key confounder in this analysis, as I men-
tioned. The protocol did not mandate how chest tubes were man-
aged. Therefore, a surgeon’s practice pattern, for example, his/her
willingness to remove a chest tube that drained 400 mL in the pre-
vious 24 hours compared with waiting for drainage to decrease to
250 mL in the previous 24 hours, would make a difference in the
timing of chest tube removal. End points such as chest tube removal
have to be looked at with that in mind. However, regarding other
end points such as mortality, lymph node dissection, and so on, I
believe the study shows that VATS lobectomy can be done and
achieve similar results to open lobectomy. Those end points are
perhaps less affected by the fact that 1 surgeon did most of the pro-
cedures in the VATS group. The study demonstrates that VATS
lobectomy can achieve those similar goals.
Dr Mitchell. Second, there were 10 times as many patients in
the open resection group compared with the VATS group. There
were other differences as well, such as in the performance status.
Do you have any concerns about the validity of your results based
on these discrepancies between the 2 groups given the statistical
methods and scoring variables used?
Dr Scott. I think propensity matching is probably one of the
most sophisticated methods we have for performing a nonrandom-
ized comparison such as we did here. The alternative is to do some-
thing called case matching where you find 66 patients in the open
resection group who are similar to the 66 patients in the VATS
lobectomy group. Problems with the case-matching approach in-
clude accurately identifying similar patients from each group (ie,
how does one determine how similar is similar enough?) and the
fact that a significant number of patients would be excluded from
the analysis. This can actually increase the amount of bias in the
analysis. The fact that one has a large control group is actually
favorable for this type of statistical analysis.
Dr Mitchell. Finally, a VATS approach was used selectively in
the Z30 trial at the discretion of the operating surgeon. Could you
comment onhow this factmight have affected the results inyour trial?
Dr Scott. I hope that the differences we saw in baseline charac-
teristics were corrected by the propensity matching, and therefore
the patients were as similar as possible. That gets at the heart of
doing this kind of nonrandomized comparison. The choice by
a given surgeon of whether to offer a VATS or open procedure
should be accounted for by the statistical method because both
groups of patients should be similar.rdiovascular Surgery c Volume 139, Number 4 981
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SDr Robert Cerfolio, MD (Birmingham, Ala). Walter, this is an
interesting article. However, I come to meeting after meeting and
listen, and I keep hearing that VATS is better, and I keep waiting
for some data to convince me, and, once again, no offense, but
this is not it.
Did you compare DrMcKenna’s open cases with DrMcKenna’s
VATS cases? Because that is really what the article was. In other
words, did you look at the time frame for Rob’s open thoracotomies
and were the chest tubes removed as quickly as in the VATS cases?
I know we do at UAB, and we do some, although not many VATS
lobectomies. To me, that would be the only important data and
analysis from this study.
Finally, because I continue to hear this meeting after meeting, I
am performing VATS lobectomy now, even some robotic work,
and I see no difference in chest tube management. Perhaps I am
just a much worse VATS surgeon than you guys or maybe you
guys just don’t do your thoracotomies the way I do: spare the rib,
most of the muscle, and all the intercostal nerves. Maybe you do
not fast track these patients or have the mindset that their tubes
can come out after 1 or 2 days and they can go home after 3 days
and return to full activities after 3 or 4 weeks. I think if you just
treated the open cases more like the VATS cases you might not
see a difference. Can you comment on that?
Dr Scott. Those are 2 interesting points. I don’t think these data
settle the question, and perhaps a randomized trial is necessary, but
I am not sure there is equipoise in the general thoracic surgery com-
munity to do such a trial.
Dr McKenna did not have many patients who underwent the
open procedure to compare; therefore, the type 2 error would
probably be great, so we could not do that. We did perform an
exploratory analysis looking at centers that performed VATS lo-
bectomy compared with centers that performed open lobectomy,
and there was a trend for a shorter length of stay with open cases
as well in centers that performed VATS lobectomy as opposed to
those centers that performed only open resections. Some people
might see that as a criticism therefore or a reason to think that
VATS is not as good; I would argue the opposite, that the expe-
rience with VATS lobectomy led the surgeons to fast track their
open resections, if you will, and that there is something about the
experience of doing VATS lobectomies that benefits all the pa-
tients.
Dr Cerfolio.Okay, my only point is I would just be careful with
your conclusions given the methodology of this study.
Dr David Follette, MD (Sacramento, Calif). Dr Scott, this was
a superbly presented article. I do, however, share Dr Cerfolio’s con-
cerns. We now know that VATS lobectomy can be done safely by
experienced VATS surgeons. We also know there may be some
short-term advantages. It is not known if these apparent advantages
will really make any long-term difference.
I too share concerns about your data where the majority of cases
were done by a single surgeon who is recognized as the world’s au-
thority and has the largest experience. We are all aware of Dr
McKenna’s published results, and they certainly set a lofty standard
for all surgeons who choose this approach. If there were a broad-
based series, would the results for VATS lobectomy be compara-
ble?
Thus, I have grave concerns that essentially a single-surgeon se-
ries be compared with a group of other surgeons doing open lobec-982 The Journal of Thoracic and Cardiovascular Surgtomies. I don’t believe your subset analysis is statistically valid.
Could you please comment on this?
Dr Scott. There are always concerns when one does post hoc or
subset analyses such as this. Basically I would say that the data are
what they are. They have been analyzed in an excellent fashion by
the ACOSOG statisticians, and these are the conclusions we can
come to. As I mentioned, they need to be interpreted in light of
the fact that 1 surgeon did most of the VATS procedures.
Dr Follette. Don’t you think this is a lot like all the published
and presented studies on off-pump versus on-pump coronary by-
pass surgery? Do you believe that we should answer the question
as to open versus VATS lobectomy in a similar manner that an-
swered the off versus on-pump surgery question? As you may re-
call, Emory University conducted a statistically relevant study
that randomly assigned patients to either technique. All procedures
were done by a single cardiac surgeon with extensive experience
with both techniques. As you may recall, when the data were ana-
lyzed, there was no statistical difference in outcomes or complica-
tions between these 2 techniques. Do you think that if a high-
volume center, with extensive experience with both techniques,
would be willing to do such a study that this would answer the ques-
tion once and for all?
Dr Scott. I think that would be a good idea, and I leave it up to
those centers to take on that task.
Dr Douglas Wood, MD (Seattle, Wash). Walter, nicely pre-
sented. But, I have to take the previous criticisms and perhaps em-
phasize them even greater.
It’s not legitimate to title the article the way it is titled. This is not
really a comparison of VATS versus open. This is a comparison of
RobMcKenna versus the rest of the thoracic surgeons in the United
States. I mean you could title the article as that, ‘‘Preoperative Out-
comes of Resection for Lung Cancer: A Comparison of Dr
McKenna and the Rest of the US Thoracic Surgeons.’’ It would
be an equally legitimate title and a data analysis, albeit not as inter-
esting or provocative as a title comparing VATS with open. I ques-
tion whether this is really something that we should put in the
literature because of that. This problem of confounding, of Rob
McKenna doing 82% of the VATS cases, it just can’t be overcome
statistically.
I challenge your statement that there is not equipoise in the tho-
racic surgery community to achieve this as a randomized trial. Dr
Mitchell and I can have completely different opinions about the
validity of VATS lobectomy. He can think that VATS is abso-
lutely better, and I can be cynical and not sure about that, just
like Dr Cerfolio. That is equipoise in the thoracic surgery commu-
nity. Maybe we don’t have it individually, but we don’t have to as
long as I respect John Mitchell’s point of view and he respects my
point of view; we actually have the capability of conducting a ran-
domized trial because we recognize that it is an unanswered ques-
tion. I request that we as thoracic surgeons get off of our position
that this has already been defined, because it has not, and through
ACOSOG or other sources put forward a randomized trial and
work together.
Dr Scott. In response to your initial comments, I would point out
the strengths of this study: the standardized definitions of compli-
cations and outcomes, the prospective data collection, and the care-
fully audited data (unlike many national databases). Useful
conclusions can be drawn from these data.ery c April 2010
Scott et al General Thoracic SurgeryRegarding your second point, at meetings such as the gen-
eral thoracic surgery club, whenever someone asks for a show
of hands of those willing to participate in a randomized study
of VATS versus open lobectomy, nobody raises his or her
hand. That demonstrates a lack of equipoise in the thoracicThe Journal of Thoracic and Casurgery community in that you may think open is better, I
may think VATS is better, and I’m not willing to randomize
my patients. Unless these attitudes change, there does not cur-
rently seem to be much likelihood of a randomized trial
succeeding.rdiovascular Surgery c Volume 139, Number 4 983
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